Rituximab-a B cell targeted therapy in systemic lupus erythematosus: where do we stand?

Rheumatology (Oxford). 2022 May 5;61(5):1752-1755. doi: 10.1093/rheumatology/keac095.

Authors

Silvia Piantoni¹, Peter Korsten²

Affiliations

¹ Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy.
² Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.

PMID: 35191468
DOI: 10.1093/rheumatology/keac095

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Murine-Derived
Humans
Lupus Erythematosus, Systemic* / drug therapy
Rituximab / therapeutic use
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab